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OBJECTIVES: Partial breast irradiation (PBI) can be considered a safe alternative to
standard whole breast irradiation (WBI) in favourable early breast cancer and,
profitably, is delivered in a shorter time. Four different techniques have been de-
scribed in randomized trials (follow-up  4 years): intraoperative-radiotherapy
(IORT), delivered at the time of tumorectomy; low-dose-rate brachytherapy (LDR),
delivered in 3 days; external-beam radiotherapy (EBRT) and high-dose-rate brachy-
therapy (HDR), both delivered in 5 days. For comparison, WBI is delivered in seven
weeks. The objective of this study was to compare the cost-effectiveness of the 4
different technical approaches to PBI, for the treatment of selected favourable early
stage breast cancer patients, using current cost estimations within the Spanish
Public Health System. METHODS: A decision-analysis model was performed using
efficacy data from previous prospective trials, calculated in years without mastec-
tomy (YWM). Direct costs were estimated based on charges applied by Madrid’s
Autonomous Community, and were expressed in Euros (€). For each modality of
PBI, local recurrence rates where individualized, and charges weighted for the
frequency of its occurrence. A probabilistic sensitivity analysis was conducted to
evaluate the robustness of the results. RESULTS: A total cost of 5488.25 € was
estimated for EBRT, 6595.87 € for LDR, 7454.10 € for HDR, and 8895,71 € for IORT. The
incremental cost-effectiveness ratio (ICER) comparing IORT to EBRT was 17209.41
€/YWM. All brachytherapy techniques (LDR and HDR) were dominated. Sensitivity
analysis showed that ICER depends mainly on recurrence level after EBRT, but also
on IORT costs. CONCLUSIONS: In a Spanish Public Health Care scenario, IORT
shows a reasonable a cost-effectiveness ratio for patients with early stage breast
cancer and, due to its intrasurgical administration (same hospital admission re-
quired for surgery), should be considered a compelling alternative, in particular for
patients with complex transportation demands to access radiotherapy facilities.
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OBJECTIVES: In breast cancer, adjuvant chemotherapy is often prescribed as a
precautionary measure and sometimes unnecessarily. A diagnostic test based on
an analysis of 21 genes estimating the risk of recurrence at 10 years for women with
breast cancer in early stage has been developed (Oncotype-DX®). A cost-effective-
ness model was implemented to evaluate the long-term costs and clinical out-
comes associated with introducing this test to inform decision on adjuvant che-
motherapy in France. METHODS: A Markov model was implemented to evaluate
the impact of the test in terms of costs, life-years gained and quality-adjusted
life-years (QALYs) in French clinical practice for patients with ER , HER2-, node-
negative early-stage breast cancer, over 30 years. A strategy using the genetic test
to decide whether to administer chemotherapy or not was compared to utilization
of standard decision criteria. The model accounted for the costs of testing, adjuvant
chemotherapy and recurrence. Utilities were dependent on recurrence status and
undergoing chemotherapy. Input data were obtained from a study evaluating the
proportions of patients in which the genetic test led to change the oncologist’s
decision, as well as scientific literature and grey literature. RESULTS: The test was
associated with savings of €570 (€1600 with productivity loss cost) per patient from
societal perspective and gains of 0.15 life-years and 0.14 QALYs per patient. One-
way sensitivity analyses showed that the cost was most sensitive to the recurrence
cost and QALYs to discount rate and to the proportion of patients for whom the
decision not to give chemotherapy was reversed with the test. CONCLUSIONS: The
use of the test seems to represent efficient use of health care resources in French
practice. This test provides an opportunity to optimize treatment prescription by
avoiding unnecessary chemotherapies and by prescribing chemotherapy to
women who have not received it based on standard decision criteria.
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OBJECTIVES: The EOS 2D/3D X-ray imaging system is a novel technology with
potential clinical benefits in the evaluation of orthopaedic conditions. However,
there is no evidence on other benefits in addition to those derived from reductions
in the radiation dose. This study aims to evaluate the cost-effectiveness of EOS
compared with standard X-ray and highlight some of the typical challenges in the
evaluation of diagnostics.METHODS:A model was developed to evaluate the long-
term cost-effectiveness of EOS. Costs were from a health service perspective and
outcomes were measured as quality-adjusted life years (QALYs). Threshold analy-
sis was used to establish the necessary size of the additional health benefits and
the level of patient throughput needed for EOS to be considered cost-effective.
RESULTS: The incremental cost-effectiveness ratio (ICER) of EOS was well above
thresholds of £20,000 and £30,000 per additional QALY in all orthopaedic conditions
under base-case assumptions. Patient throughput was a major determinant of
cost-effectiveness. Threshold analysis on patient throughput showed that 17,700
to 27,600 scans per year with EOS, compared with 7,530 scans per year with com-
puted radiography (CR), were needed to achieve an ICER of £20,000 per QALY.
Health benefits over and above lower radiation would need to increase consider-
ably for EOS to be considered cost-effective. CONCLUSIONS: The health benefits
estimated from EOS as a result of radiation dose reductions were insufficient to
justify the cost of the system. EOS can only be shown to be cost-effective when
compared to CR if the utilisation of EOS is assumed to be about twice the utilisation
of CR. EOS highlights some of the difficulties of establishing the relevant care
pathway, potential indications, patient benefit from the imaging features, and pa-
tient throughput. The evaluation of EOS is an example of how methodological
challenges presented by diagnostics can be overcome.
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OBJECTIVES: Evidence from recent clinical studies has shown the benefits of SMBG
plus a structured testing program (SMBGSTG) in non-insulin treated patients
with T2DM. The Structured Testing Protocol (STeP) study found SMBGSTG can
lead to improvements in glycemic control. This study assessed the cost-effective-
ness of SMBGSTG versus SMBG alone from the Spanish health care system per-
spective in the context of recent studies of SMBG that have employed active edu-
cation programs. METHODS: A discrete event simulation model was developed to
simulate the economic and health outcomes based on A1c changes related to using
SMBGSTG or SMBG alone. Baseline A1c (8.4%) changes over 1 year (-1.2% and
-0.9% for SMBGSTG versus SMBG alone), discontinuation and hypoglycemia rates
were from the STeP study. Population and cost inputs were from published Spanish
sources. Over a lifetime horizon (30yrs), the model predicts: diabetes related com-
plications (cardiovascular disease, stroke, amputations, end stage renal disease),
hypoglycemia, life years (LYs) and quality adjusted life years (QALYs). Costs asso-
ciated with events were estimated. Benefits and costs were discounted at 5%. Un-
certainty in model estimates, such as changes in price per strip, treatment groups,
program component, and A1c differences, was explored with sensitivity analyses.
RESULTS: SMBGSTG was predicted to reduce complications and associated costs.
Lowering A1c and consequent complications prevention with SMBGSTG trans-
lated into a dominant incremental cost-effectiveness ratio. Comparisons with a
group not utilizing SMBG yielded similar results. CONCLUSIONS: In the long term,
SMBGSTG is a cost-effective option compared to SMBG alone. An A1c reduction of
0.3% is a cost-effective outcome. Decison makers should consider designing pro-
grams to educate patients about SMBGSTG.
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OBJECTIVES: To assess the cost-effectiveness of TAVI compared with standard
therapy consisting mainly of balloon aortic valvuloplasty (BAV) in patients with
severe aortic stenosis who are ineligible for conventional aortic valve replacement
(AVR) from the perspective of the Ontario health care payer. METHODS: A micro-
simulation decision analytical model was developed to estimate the incremental
costs and benefits associated with both interventions over a lifetime time horizon.
Monthly adverse event and patient mortality rates were determined using data
from the PARTNER randomized control trial (cohort B). Quality of life values were
determined through literature review, expert opinion, and data provided by the
PARTNER investigators. The London Health Sciences Centre Case Costing Initiative
and the Canadian Institute for Health Administration (CIHI) were used to estimate
costs. Extensive sensitivity analyses were performed to explore the impact of un-
certainty surrounding model parameters on the resultant cost-effectiveness esti-
mates. The primary outcome measure was the incremental cost-effectiveness ra-
tio (ICER) with benefits expressed as quality-adjusted life years (QALYs). Costs were
expressed in 2011 CAD$. Both costs and benefits were discounted at 5%. RESULTS:
The base case ICER was approximately $38,448 per QALY gained. The results of the
sensitivity analyses yielded ICERs ranging from approximately $32,238/QALY to
$43,887/QALY. ICER estimates were most sensitive to changes in the cost of the
Edwards SapienTMDevice. CONCLUSIONS: At cost-effectiveness thresholds nor-
mally used to define value for money in health care, TAVI represents a cost-effec-
tive treatment option for patients with severe aortic stenosis who are currently
ineligible to undergo conventional aortic valve replacement in the province of
Ontario.
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